<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2182">
  <stage>Registered</stage>
  <submitdate>16/11/2008</submitdate>
  <approvaldate>16/11/2008</approvaldate>
  <nctid>NCT00792714</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients</studytitle>
    <scientifictitle>Determination of the Pharmacokinetics of Inhaled Mannitol After Single and Multiple Dosing in Cystic Fibrosis Patients</scientifictitle>
    <utrn />
    <trialacronym>DPM-PK-102</trialacronym>
    <secondaryid>DPM-PK-102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Mannitol

Treatment: drugs: Mannitol
400mg twice daily for 7 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The general objective of the study is to estimate the systemic pharmacokinetics of mannitol after single and multiple dosing of IDPM 400 mg to adult and paediatric cystic fibrosis patients.</outcome>
      <timepoint>8 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have given written informed consent to participate in this study in accordance with
             local regulations

          -  Have a confirmed diagnosis of cystic fibrosis (sweat test and/or genotype)

          -  Be aged &gt;6 years (6-11 for paediatrics, 12-17 for adolescents and 18 years for adults)

          -  Have FEV1 &gt; 30 % and &lt; 90% predicted</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Be investigators, site personnel directly affiliated with this study, or their
             immediate families. Immediate family is defined as a spouse, parent, child or sibling,
             whether biologically or legally adopted.

          -  Be considered "terminally ill" or listed for lung transplantation

          -  Have had a lung transplant

          -  Be using nebulised hypertonic saline

          -  Have had a significant episode of haemoptysis (&gt; 60 mL) in the three months prior to
             enrolment

          -  Have had a myocardial infarction in the three months prior to enrolment

          -  Have had a cerebral vascular accident in the three months prior to enrolment

          -  Have had major ocular surgery in the three months prior to enrolment

          -  Have had major abdominal, chest or brain surgery in the three months prior to
             enrolment

          -  Have a known cerebral, aortic or abdominal aneurysm

          -  Be breast feeding or pregnant, or plan to become pregnant while in the study

          -  Be using an unreliable form of contraception (female patients at risk of pregnancy
             only)

          -  Be participating in another investigative drug study, parallel to, or within 4 weeks
             of study entry (except inhaled mannitol)

          -  Not able to maintain a mannitol free diet from Day -2 until Day 8 of the treatment
             phase.

          -  Have a known allergy to mannitol

          -  Be using beta blockers

          -  Have uncontrolled hypertension - systolic blood pressure &gt; 190 and / or diastolic
             blood pressure &gt; 100

          -  Have a condition or be in a situation which in the Investigator's opinion may put the
             subject at significant risk, may confound results or may interfere significantly with
             the patient's participation in the study

          -  Be MTT positive.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Mater Adult Hospital - Brisbane</hospital>
    <hospital>Royal Children's Hospital - Melbourne</hospital>
    <postcode>4101 - Brisbane</postcode>
    <postcode>3052 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmaxis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The general objective of the study is to estimate the systemic pharmacokinetics of mannitol
      after single and multiple dosing of IDPM 400 mg to adult and paediatric cystic fibrosis
      patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00792714</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>